Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Breakthrough research reshapes understanding of T cell immune responses

24

Mar 2026

Breakthrough research reshapes understanding of T cell immune responses

In a paradigm breaking study, Dr. Pavan Reddy, director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine (BCM) and his team, in collaboration with Drs. Arul Chinnaiyan, S P Hicks Endowed Professor of Pathology, and Marcin Cieslik, assistant professor of pathology, both from University of Michigan Rogel Cancer Center, discovered a novel way the immune system, specifically T-cells, attack their target cells, reshaping long-held assumptions in immunology and demonstrating direct implications for the field of cancer immunology and bone marrow transplantation.

Personalized radiotherapy reduces the risk of breast cancer recurrence

24

Mar 2026

Personalized radiotherapy reduces the risk of breast cancer recurrence

The chances of breast cancer recurring remain very low when patients are treated with radiotherapy that is tailored to their individual risk following chemotherapy and surgery. These are the findings of a ten-year study presented at the 15th European Breast Cancer Conference (EBCC15) in Barcelona today (Wednesday).

Nepal and Afghanistan show how abrupt aid cuts can unravel essential care

24

Mar 2026

Nepal and Afghanistan show how abrupt aid cuts can unravel essential care

Abrupt cuts to external health aid can destabilize multiple essential services simultaneously in fragile, donor-dependent settings, as illustrated by Nepal and Afghanistan. The paper argues that donor withdrawal is not just a resilience test, but also an ethical and governance issue that should be managed through “transition discipline.”

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.